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e set out to determine the mutation detection rate in 50 subjects referred with possible Stargardt disease (STGD) using direct sequencing of the ABCA4 gene (GenBank NM_000350). Pathogenic mutations in ABCA4 have been found to cause Stargardt disease (STGD)/fundus flavimaculatus as well as some cases of cone-rod dystrophy, autosomal recessive retinitis pigmentosa, and bull's-eye maculopathy. 1, 2 Mutation detection rates reported in patients are highly variable, depending on multiple factors including the phenotype and mutation detection method used. [3] [4] [5] Because next-generation sequencing is likely to be introduced into clinical diagnostics, we revisited direct (Sanger) sequencing, currently the gold standard for mutation detection, in a large group of patients with STGD to determine the number of patients receiving a confident molecular diagnosis using a sequencing approach.
Methods. Fifty patients with STGD or other possible ABCA4 retinopathies were recruited. All patients (and involved relatives) were counseled and consented according to the Declaration of Helsinki, and the study was approved by the local ethics committee. Full ophthalmic history, examination, and electrophysiology were performed. The patients' DNA was extracted, and direct (dideoxy/Sanger) sequencing of all ABCA4 exons and a 25-base pair flanking sequence was performed using standard protocols. The pathogenicity of all sequence variants was determined using standard software (Alamut version 1.5; Interactive Biosoftware). Multiplex ligationdependent probe amplification analysis (P151 and P152 kits; MRC-Holland) was used to identify copy number variants. We determined phase and segregation when possible. A confident molecular diagnosis was defined as the presence of 2 or more pathogenic mutations.
Results. Of 50 patients, 34 had a phenotype compatible with STGD. Of these 34 patients, 27 (79%) had at least 2 pathogenic mutations; 7 of the 34 patients had a single mutation identified, 2 of the 34 had premature termination codons (stop codon and frameshift), and 5 of the 34 had known missense mutations. The identification of a single mutation supports the clinical diagnosis but is not conclusive; however, the carrier rate is estimated to be 1 in 35 to 1 in 50 patients, so we would not expect as many as one-fifth of our patients to be carriers by chance alone. Among the 50 patients, 11 were diagnosed as having STGD by other centers in the past but on current clinical review were reclassified as shown in the Table, reflecting both progression of the disorder and the presence of phenocopies or misdiagnoses. In 5 of the 11 patients, the identification of 2 pathogenic mutations confirmed the historical diagnosis and all had chorioretinal atro- phy on current clinical examination, consistent with progression of the disorder. 5 One of the 11 patients with chorioretinal atrophy (subject 40) had a single stop codon, again strongly supporting the original clinical diagnosis. Six of the 11 patients did not have pathogenic mutations in ABCA4. Two of the 6 have since been found to have mutations in other genes: CDH3 in subject 41 6 and CRX in subject 47.
7 Subject 49 (with late-onset pattern dystrophy) has a disease-associated allele of unknown mechanism and a missense variant of unknown significance, making the molecular diagnosis in this patient uncertain. In 3 of the 6 patients with a historical diagnosis of STGD and atypical phenotypes (subjects 42, 48, and 50), the molecular diagnosis remains unknown and further investigations are ongoing. Two of 5 patients with bull's-eye maculopathy had 2 pathogenic mutations, 1 of the 5 had a single known missense mutation, and 2 of the 5 had no mutations, confirming that bull's-eye macu- lopathy is genetically heterogeneous. A total of 10 novel mutations were identified (Table) .
Comment.
A range of phenotypes can be associated with mutations in ABCA4; therefore, genetic testing is important in establishing a firm diagnosis. Direct sequencing in our cohort resulted in a confident molecular diagnosis in 79% of patients with an STGD phenotype, supporting its use as a diagnostic tool. By comparison, the highest reported detection rate in a smaller group of patients was 68% using direct sequencing 4 and 63.5% using arrayed primer extension. 5 In patients with a historical diagnosis of STGD, more than 50% had mutations in ABCA4 testing but the remainder did not and will require further investigation. Among our patients with STGD, 21% had only a single mutation; further research is required to determine the explanation for this. In our cohort, no cases could be explained by copy number variants. Sequencing identified several novel mutations and has the highest detection rate of available technologies. Despite this, further research on the underlying genetic mechanisms in ABCA4 retinopathies is required. ; splice, missense, and nonsense mutations have since been described.
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Report of a Case. A 48-year-old man had a 21-year history of deterioration of central vision. The original diagnosis was Stargardt disease. Initial symptoms at age 17 years included photosensitivity, abnormal color vision, and central scotomata. His sister has the same phenotype and the parents were likely to be related. The proband and his sister both gave a history of having very fine, sparse hair that never thickened, with a persistently visible scalp ( Figure 1A) . Funduscopy in the proband revealed bilateral symmetrical macular degeneration with sparing of the peripheral retina ( Figure 1B and C) . Visual acuities were 6/760 OD and 6/96 OS. Goldmann visual field testing showed bilateral central scotomata ( Figure 1D ). Electrophysiology showed extinguished pattern electroretinograms, normal scotopic responses, and significant reduction in amplitudes of both a and b waves in the standard flash electroretinogram and photopic responses. The electro-oculogram light rise was normal in both eyes. 
